Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC)

Authors :: David Cunningham
K. Krishnan
F. Xu
Mario Edmundo Barugel
J. Tabernero
Ronald Burkes
Salvatore Siena
J.-Y. Douillard
J. Cassidy
Yves Humblet
Source :: Journal of Clinical Oncology. 29:3510-3510
Publication Year :: 2011
Publisher :: American Society of Clinical Oncology (ASCO), 2011.
Abstract: 3510^ Background: The primary analysis of PRIME demonstrated that pmab + FOLFOX4 significantly improved progression-free survival (PFS) vs FOLFOX4 for 1st line mCRC in patients (pts) with wild-type...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Colorectal cancer
business.industry
First line
medicine.disease
Prime (order theory)
Surgery
Internal medicine
medicine
Panitumumab
In patient
business
medicine.drug

Tools